Pharma Update

Off-the-shelf CAR-Ts for hematologic malignancies Highly differentiated new generation of fully allogeneic CAR-Ts Long-lived self-renewing stem cell memory T cells TSCM Cell Stem cell memory High-fidelity, proprietary gene editing technology POSEIDA THERAPEUTICS Cost, scale and reach Self-renewing • Long-lived • Multipotent • Healthy donor derived MHC I knock-out TCR knock-out Roche • T SCM - ideal cell type for CAR-T due to greater safety and durability • piggy BacⓇ - superior non-viral gene insertion technology Addressing both Graft v Host and Host v Graft alloreactivity with Cas-CLOVER™ Gene Editing • Proprietary booster molecule enables potential to deliver 100's of doses translating into lower cost, lower wait time and broader patient reach Ph I open-label dose-escalation study of P-BCMA-ALLO1 in MM ongoing: Early signs of efficacy and favorable tolerability profile P-CD19CD20-ALLO1 IND approved Q2 2023, Ph I in B-cell malignancies expected to start early 2024 Additional allogeneic CAR-Ts in development for MM and AML • Program in partnership with Poseida; Kocoglu M et al., ESMO I-O 2022; IND=investigational new drug application; CAR-T-chimeric antigen receptor T-cell; MM-multiple myeloma; AML-Acute myeloid leukemia 24 94

View entire presentation